Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma

Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. In the current Phase II trial, the authors evaluated the feasibility, toxicity, and efficacy of weekly docetaxel in the treatment of elderly patients with newly diagnosed advanced nonsmall cell lung carcinoma.

[1]  G. Luporini,et al.  Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. , 1999, Journal of the National Cancer Institute.

[2]  C. Hudis,et al.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Hainsworth,et al.  Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. James,et al.  Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Choy,et al.  Phase I trial of weekly paclitaxel in advanced lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Whang‐Peng,et al.  Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Norton,et al.  Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Crawford,et al.  Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Shepherd,et al.  Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. , 1996, European journal of cancer.

[10]  M. Friedlander,et al.  Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Shepherd.  Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview , 1995, Anti-cancer drugs.

[12]  J. Hainsworth,et al.  Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Hansen,et al.  Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Bezwoda,et al.  Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Wanders,et al.  Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) , 1994, British Journal of Cancer.

[16]  M. Kris,et al.  Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Lippman,et al.  Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P Chomy,et al.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Winn,et al.  Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[20]  T Anderson,et al.  Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. , 1993, Journal of the National Cancer Institute.

[21]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .